Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
KRAS mutation
i
Other names:
KRAS, KRAS1, KRAS2, Kirsten rat sarcoma viral oncogene homolog
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
3845
Related biomarkers:
Expression
Mutation
CNA
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
KRAS mutation
Biliary Tract Cancer
KRAS mutation
Biliary Tract Cancer
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 3wk
trastuzumab + pertuzumab
Resistant: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
trastuzumab + pertuzumab
Resistant
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks (New C3)
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 3wk
AGEN2034 + AGEN1181
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 3 weeks
AGEN2034 + AGEN1181
Sensitive
:
C3
ASCO-GI 2023 - 3 weeks - (New C3)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 3 weeks (New D)
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 3wk
alpelisib + ribociclib
Sensitive: D – Preclinical
ASCO-GI 2023 - 3 weeks
alpelisib + ribociclib
Sensitive
:
D
ASCO-GI 2023 - 3 weeks - (New D)
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
cetuximab
Resistant: B - Late Trials
cetuximab
Resistant
:
B
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
trifluridine/tipiracil
Sensitive: B - Late Trials
trifluridine / tipiracil
Sensitive
:
B
trifluridine/tipiracil
Sensitive: B - Late Trials
trifluridine / tipiracil
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
pembrolizumab
Sensitive: B - Late Trials
pembrolizumab
Sensitive
:
B
KRAS mutation
Acute Myelogenous Leukemia
KRAS mutation
Acute Myelogenous Leukemia
gilteritinib
Resistant: B - Late Trials
gilteritinib
Resistant
:
B
gilteritinib
Resistant: B - Late Trials
gilteritinib
Resistant
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
abemaciclib
Sensitive: B - Late Trials
abemaciclib
Sensitive
:
B
abemaciclib
Sensitive: B - Late Trials
abemaciclib
Sensitive
:
B
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
KRAS mutation
Lung Non-Squamous Non-Small Cell Cancer
bevacizumab + atezolizumab
Sensitive: B - Late Trials
bevacizumab + atezolizumab
Sensitive
:
B
bevacizumab + atezolizumab
Sensitive: B - Late Trials
bevacizumab + atezolizumab
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
gefitinib
Sensitive: B - Late Trials
gefitinib
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
selumetinib
Sensitive: B - Late Trials
selumetinib
Sensitive
:
B
selumetinib
Sensitive: B - Late Trials
selumetinib
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
Immunotherapy
Sensitive: B - Late Trials
Immunotherapy
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
nivolumab
Sensitive: B - Late Trials
nivolumab
Sensitive
:
B
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
regorafenib
Sensitive: B - Late Trials
regorafenib
Sensitive
:
B
regorafenib
Sensitive: B - Late Trials
regorafenib
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
erlotinib
Resistant: B - Late Trials
erlotinib
Resistant
:
B
erlotinib
Resistant: B - Late Trials
erlotinib
Resistant
:
B
KRAS mutation
Thyroid Gland Medullary Carcinoma
KRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: B - Late Trials
cabozantinib capsule
Sensitive
:
B
cabozantinib capsule
Sensitive: B - Late Trials
cabozantinib capsule
Sensitive
:
B
KRAS mutation
Thyroid Gland Medullary Carcinoma
KRAS mutation
Thyroid Gland Medullary Carcinoma
cabozantinib capsule
Sensitive: B - Late Trials
cabozantinib capsule
Sensitive
:
B
cabozantinib capsule
Sensitive: B - Late Trials
cabozantinib capsule
Sensitive
:
B
KRAS mutation
Ovarian Cancer
KRAS mutation
Ovarian Cancer
binimetinib
Sensitive: B - Late Trials
binimetinib
Sensitive
:
B
binimetinib
Sensitive: B - Late Trials
binimetinib
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
durvalumab + tremelimumab
Sensitive: B - Late Trials
durvalumab + tremelimumab
Sensitive
:
B
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
pembrolizumab + abemaciclib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + abemaciclib
Sensitive
:
C2
pembrolizumab + abemaciclib
Sensitive: C2 – Inclusion Criteria
pembrolizumab + abemaciclib
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
bevacizumab + PCM-075
Sensitive: C2 – Inclusion Criteria
bevacizumab + PCM-075
Sensitive
:
C2
bevacizumab + PCM-075
Sensitive: C2 – Inclusion Criteria
bevacizumab + PCM-075
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
afatinib + selumetinib
Sensitive: C2 – Inclusion Criteria
afatinib + selumetinib
Sensitive
:
C2
afatinib + selumetinib
Sensitive: C2 – Inclusion Criteria
afatinib + selumetinib
Sensitive
:
C2
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
bevacizumab
Sensitive: C2 – Inclusion Criteria
bevacizumab
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
eFT226
Sensitive: C2 – Inclusion Criteria
eFT226
Sensitive
:
C2
eFT226
Sensitive: C2 – Inclusion Criteria
eFT226
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
VS-6766
Sensitive: C2 – Inclusion Criteria
VS-6766
Sensitive
:
C2
VS-6766
Sensitive: C2 – Inclusion Criteria
VS-6766
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
GSK3070785
Sensitive: C2 – Inclusion Criteria
GSK3070785
Sensitive
:
C2
GSK3070785
Sensitive: C2 – Inclusion Criteria
GSK3070785
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
anlotinib
Sensitive: C2 – Inclusion Criteria
anlotinib
Sensitive
:
C2
anlotinib
Sensitive: C2 – Inclusion Criteria
anlotinib
Sensitive
:
C2
KRAS mutation
Non Small Cell Lung Cancer
KRAS mutation
Non Small Cell Lung Cancer
sunitinib
Sensitive: C2 – Inclusion Criteria
sunitinib
Sensitive
:
C2
sunitinib
Sensitive: C2 – Inclusion Criteria
sunitinib
Sensitive
:
C2
KRAS mutation
Ovarian Cancer
KRAS mutation
Ovarian Cancer
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
VS-6766 + VS-6063
Sensitive: C2 – Inclusion Criteria
VS-6766 + VS-6063
Sensitive
:
C2
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
bevacizumab + cetuximab
Sensitive: C2 – Inclusion Criteria
bevacizumab + cetuximab
Sensitive
:
C2
bevacizumab + cetuximab
Sensitive: C2 – Inclusion Criteria
bevacizumab + cetuximab
Sensitive
:
C2
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
palbociclib + binimetinib
Sensitive: C2 – Inclusion Criteria
palbociclib + binimetinib
Sensitive
:
C2
palbociclib + binimetinib
Sensitive: C2 – Inclusion Criteria
palbociclib + binimetinib
Sensitive
:
C2
KRAS mutation
Melanoma
KRAS mutation
Melanoma
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
trametinib
Sensitive: C2 – Inclusion Criteria
trametinib
Sensitive
:
C2
KRAS mutation
Colorectal Cancer
KRAS mutation
Colorectal Cancer
cetuximab + selumetinib
Sensitive: C2 – Inclusion Criteria
cetuximab + selumetinib
Sensitive
:
C2
cetuximab + selumetinib
Sensitive: C2 – Inclusion Criteria
cetuximab + selumetinib
Sensitive
:
C2
KRAS mutation
Acute Myelogenous Leukemia
KRAS mutation
Acute Myelogenous Leukemia
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
venetoclax
Resistant: C3 – Early Trials
venetoclax
Resistant
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login